Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 15/20 | 0.53 |
| ▸ | SMARCA4 | P51532 | 15/20 | 0.53 |
| ▸ | PBRM1 | Q86U86 | 16/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30797027 | 1.00 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL23301459 | 1.00 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL29910593 | 0.95 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1OPRM1 | |
| SCHEMBL23301401 | 0.95 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1OPRM1 | |
| SCHEMBL29910839 | 0.93 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1BRD4OPRM1 | |
| SCHEMBL23301166 | 0.93 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1BRD4OPRM1 | |
| SCHEMBL29943546 | 0.92 | SMARCA2 (0.48) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL23301482 | 0.89 | SMARCA2 (0.52) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL29910770 | 0.89 | SMARCA2 (0.52) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL23303211 | 0.89 | PBRM1 (0.64) | SMARCA2SMARCA4PBRM1BRD4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |